Research has found it is possible to temporarily reverse it by going on a strict, ultra-low calorie diet. However, this is ...
UNSW medical researchers say more Australians with type 2 diabetes need to be offered add-on medications that would better ...
More Australians with type 2 diabetes should gain access to potentially lifesaving medications, a new analysis has found.UNSW medical researchers say ...
Metabolize, a breakthrough solution to naturally address obesity, is excited to announce the publication of groundbreaking findings on their newly licensed metabolite, ...
KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...
Semaglutide did not increase the risk of depression, suicidal thoughts or suicidal behavior in people without known mental ...
A new study found that most people taking ... experts said. Stopping a GLP-1 too early doesn't always give the drug time to work and, if the drug is taken long enough to achieve results, could ...
GLP-1 agonist ... study. There were zero cases of drug-induced liver injury or persistent liver enzyme elevations reported across the two studies. The 36-week global study is expected to use ...
For example, Teva Pharmaceutical Industries Ltd recently launched the first generic injectable version of this GLP-1 drug. Although liraglutide was administered as an oral DehydraTECH-enabled dose in ...
Wegovy is part of a class of drugs called GLP-1 Receptor Agonists. Taking a weight loss drug may also help reduce the risk of heart attack, stroke and cardiac death, data shows. Wegovy ...
"The growth of GLP-1 agonists to treat obesity has been incredible and highly effective in the short run, but data shows that 67% of patients discontinue use due ... The study is designed to ...
